Gemtuzumab ozogamicin

Name: Gemtuzumab ozogamicin
Brand: MedChemExpress
SKU: HY-109539
Rating: 4.5 (1 reviews)

Cat. No.: HY-109539 Purity: 98.0%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin (IgG4) antibody directed against CD33 that is conjugated to the cytotoxic drug Calicheamicin (HY-19609). Calicheamicin is a cytotoxic antibiotic. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia (AML).

For research use only. We do not sell to patients.

Gemtuzumab ozogamicin Chemical Structure

CAS No. : 220578-59-6

Size	Price	Stock	Quantity
100 μg	USD 1500	In-stock	Estimated Time of Arrival: December 31
200 μg	USD 2680	In-stock	Estimated Time of Arrival: December 31
500 μg	USD 5850	In-stock	Estimated Time of Arrival: December 31

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Gemtuzumab ozogamicin (1-250 ng/mL ; 72 hours) has cell cytotoxicity in CD33-positive cells^[1].
Gemtuzumab ozogamicin is an ADC. After binding of the antibody to CD33 and subsequent internalization, Calicheamicin mediates cytotoxicity to CD33-positive myeloid cells primarily through induction of DNA damage and subsequent apoptosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	CD33-positive and CD33-deficient cells (HL60, HL60R, Kasumi-1, MV4-11, MV4-11R, primary CD34-positive HSPCs and primary AML blasts)
Concentration:	0, 1, 5, 10, 25, 50, 100, 250 ng/mL
Incubation Time:	72 hours
Result:	Wildtype HL60 exhibited the highest sensitivity to GO (IC₅₀=1.37 ng/mL), and almost all HL60 cells died at 5 ng/mL concentration. HL60R, Kasumi-1, MV4-11 and MV4-11R showed similar sensitivity, with IC₅₀s of 2.28, 3.19, 3.63 and 5.36 ng/mL, respectively. IC₅₀ in CD33-negative HL60R, Kasumi-1, MV4-11 and MV4-11R cells also increased significantly to 95.53, 50.78, 72.74 and 66.8 ng/mL, respectively.

Clinical Trial

CAS No.

220578-59-6

Appearance

Solid

Color

White to off-white

SMILES

[Gemtuzumab ozogamicin]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Purity & Documentation

Purity: 98.0%

Select Batch:

Data Sheet (267 KB) SDS (251 KB)

COA (231 KB)

Handling Instructions (2659 KB)

References

[1]. Yi Liu, et al. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Int J Cancer. 2022 Apr 1;150(7):1141-1155. [Content Brief]

[2]. Baron J, et al. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018;11(6):549-559. [Content Brief]